Home / Expertise / Life Sciences & Healthcare / Pharmaceuticals


United Kingdom

With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

Operating in one of the most highly regulated sectors, you need lawyers who are leaders in their field. We have expertise in the regulation of medicines, clinical trials, promotion and marketing, anti-corruption and industry codes, IP, data protection, competition, public procurement, tax and transfer pricing.

Whether you are looking to acquire a developmental pipeline from another company or streamline your own pipeline/portfolio to focus on particular therapeutic areas, we have relevant experience advising on product acquisition and disposal, R&D collaboration, supply chain, and licensing agreements. Having acted on large cross-border licensing and M&A deals for our sector-leading clients, our multi-disciplinary team can advise on transactions of any size and complexity.

We also represent clients in domestic and cross-border litigation, whether relating to commercial disputes, defence of product liability claims, protecting intellectual property rights or judicial review and public procurement challenges.

Read more Read less
High­lights of our ex­per­i­ence in Phar­ma­ceut­ic­als in the UK
Almir­all, S.A. on the trans­fer of its res­pir­at­ory fran­chise for an ini­tial con­sid­er­a­tion of USD 875m on com­ple­tion, and up to USD 1.22bn in de­vel­op­ment, launch and sales-re­lated mile­stone pay­ments.Take­da...
Law-Now: Lifes­ci­ences
Vis­it Law-Now for leg­al know-how and com­ment­ary


Show only
30 October 2019
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s...
In­ter­na­tion­al law firm CMS has ad­vised glob­al private equity firm Ad­vent In­ter­na­tion­al and its port­fo­lio com­pany, Zentiva, on its ac­quis­i­tion of the CEE busi­ness of glob­al gen­er­ic and over-the-counter...